These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 15485995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [Abstract] [Full Text] [Related]

  • 6. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 9. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A, Inaba M, Furumitsu Y, Okamoto K, Yukioka K, Goto H, Nishizawa Y.
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [Abstract] [Full Text] [Related]

  • 12. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R.
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [Abstract] [Full Text] [Related]

  • 13. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.
    Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M.
    Ann Rheum Dis; 2006 Jan; 65(1):26-9. PubMed ID: 15941839
    [Abstract] [Full Text] [Related]

  • 14. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B, Cameron L, Ouellet M, White B.
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [Abstract] [Full Text] [Related]

  • 15. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis.
    Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P.
    Ther Drug Monit; 2010 Apr; 32(2):232-6. PubMed ID: 20216124
    [Abstract] [Full Text] [Related]

  • 16. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy.
    Lemarechal H, Allanore Y, Chenevier-Gobeaux C, Kahan A, Ekindjian OG, Borderie D.
    Clin Chim Acta; 2006 Oct; 372(1-2):147-53. PubMed ID: 16716286
    [Abstract] [Full Text] [Related]

  • 19. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
    Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, Devogelaer JP, Houssiau FA.
    Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
    [Abstract] [Full Text] [Related]

  • 20. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
    Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O.
    Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.